Salarius Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Salarius Pharmaceuticals's earnings have been declining at an average annual rate of -22.5%, while the Biotechs industry saw earnings growing at 10.1% annually. Revenues have been declining at an average rate of 52.6% per year.
Key information
-22.5%
Earnings growth rate
48.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -52.6% |
| Return on equity | -272.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Salarius Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -6 | 5 | 2 |
| 31 Mar 24 | 0 | -9 | 6 | 4 |
| 31 Dec 23 | 0 | -13 | 6 | 7 |
| 30 Sep 23 | 0 | -18 | 7 | 0 |
| 30 Jun 23 | 0 | -30 | 7 | 22 |
| 31 Mar 23 | 0 | -31 | 7 | 20 |
| 31 Dec 22 | 0 | -32 | 7 | 16 |
| 30 Sep 22 | 0 | -29 | 7 | 0 |
| 30 Jun 22 | 0 | -19 | 7 | 0 |
| 31 Mar 22 | 1 | -17 | 6 | 0 |
| 31 Dec 21 | 2 | -13 | 6 | 0 |
| 30 Sep 21 | 3 | -11 | 6 | 0 |
| 30 Jun 21 | 5 | -9 | 5 | 0 |
| 31 Mar 21 | 5 | -8 | 6 | 0 |
| 31 Dec 20 | 5 | -8 | 6 | 0 |
| 30 Sep 20 | 5 | -7 | 7 | 0 |
| 30 Jun 20 | 4 | -8 | 9 | 0 |
| 31 Mar 20 | 4 | -7 | 8 | 0 |
| 31 Dec 19 | 3 | -7 | 8 | 0 |
| 30 Sep 19 | 3 | -6 | 7 | 0 |
| 30 Jun 19 | 3 | -4 | 4 | 0 |
| 31 Mar 19 | 2 | -3 | 4 | 0 |
| 31 Dec 18 | 2 | -2 | 2 | 0 |
| 30 Sep 18 | 1 | -2 | 1 | 0 |
| 31 Dec 17 | 2 | -2 | 1 | 0 |
| 31 Dec 16 | 3 | -1 | 1 | 0 |
Quality Earnings: FP10 is currently unprofitable.
Growing Profit Margin: FP10 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FP10 is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare FP10's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FP10 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: FP10 has a negative Return on Equity (-272.14%), as it is currently unprofitable.